Amemiya Takahiro, Suzuki Hiroshi
Faculty of Pharmaceutical Sciences, Teikyo Heisei University, Tokyo, Japan.
Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan.
Cancer Diagn Progn. 2025 Sep 1;5(5):552-556. doi: 10.21873/cdp.10469. eCollection 2025 Sep-Oct.
BACKGROUND/AIM: Although rituximab is used to treat a range of diseases, the high frequency of rituximab-associated infusion reactions (IRs) poses a clinical challenge. This study aimed to identify pre-treatment risk factors associated with rituximab-induced IRs using retrospective patient data.
We retrospectively analyzed the medical records of patients treated with rituximab. Data were compared between patients with and without IRs.
Among the variables assessed, an elevated C-reactive protein (CRP) level prior to rituximab administration was significantly associated with IR occurrence (odds ratio=2.591; 95% confidence interval=1.160-5.791; 0.020).
Elevated pre-medication levels of CRP are a significant risk factor associated with the use of rituximab, thereby highlighting the need for close monitoring of patients receiving rituximab who present with elevated CRP levels prior to the initiation of therapy.
背景/目的：尽管利妥昔单抗用于治疗多种疾病，但利妥昔单抗相关输注反应（IRs）的高发生率带来了临床挑战。本研究旨在利用回顾性患者数据确定与利妥昔单抗诱导的IRs相关的治疗前风险因素。
我们回顾性分析了接受利妥昔单抗治疗的患者的病历。对发生IRs和未发生IRs的患者的数据进行了比较。
在评估的变量中，利妥昔单抗给药前C反应蛋白（CRP）水平升高与IRs的发生显著相关（比值比=2.591；95%置信区间=1.160 - 5.791；P = 0.020）。
用药前CRP水平升高是与使用利妥昔单抗相关的一个显著风险因素，从而突出了对治疗开始前CRP水平升高的接受利妥昔单抗治疗的患者进行密切监测的必要性。
